Director/PDMR Shareholding

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 18 November 2016 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”)

To download this report as a PDF file click here.